Neurological and Neuropsychiatric Manifestations of Pediatric Inflammatory Multisystem Syndrome (PIMS/MIS-C): A Narrative Review.

Publication date: Aug 31, 2026

Background: Pediatric inflammatory multisystem syndrome (PIMS), also referred to as multisystem inflammatory syndrome in children (MIS-C), is a rare but serious post-infectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection characterized by systemic hyperinflammation and multiorgan involvement. New-onset neurological and psychiatric symptoms have emerged as critical clinical features, occurring in approximately 12-27% of pediatric patients aged 2-15 years (median age, 10 years) and often indicating a more severe disease course. This narrative review aims to provide a comprehensive overview of the current literature regarding the neurological and psychiatric manifestations of PIMS/MIS-C, focusing on epidemiology, pathophysiology, clinical presentation, neuroimaging findings, biomarkers, treatment strategies, and outcomes. Methods: A narrative literature review was conducted to synthesize current evidence on the neurological and psychiatric spectrum of PIMS/MIS-C. Evaluated parameters included clinical presentations ranging from common symptoms (such as headache, encephalopathy, altered mental status, and seizures) to rare complications (such as ischemic stroke, acute disseminated encephalomyelitis, Guillain-BarrcE9 syndrome, and cerebral edema), alongside associated psychiatric disturbances, diagnostic findings, and therapeutic approaches. Results: Neurological and psychiatric manifestations significantly impact the clinical trajectory of PIMS/MIS-C. Acute symptoms include headache, encephalopathy, seizures, and psychiatric disturbances like behavioral changes, hallucinations, delirium, anxiety, and sleep disorders. Neuroimaging in many cases reveals reversible lesions of the splenium of the corpus callosum, while electroencephalography typically demonstrates diffuse slowing consistent with encephalopathy. Early recognition and prompt administration of immunomodulatory therapy-primarily intravenous immunoglobulin and corticosteroids-correlate with favorable neurological recovery in the majority of patients. However, current evidence remains largely observational and heterogeneous, precluding definitive causal conclusions regarding this treatment-outcome relationship. Affected children more frequently require intensive care unit admission and remain at risk for persistent cognitive, behavioral, and psychiatric sequelae. Conclusions: Neurological and psychiatric complications in PIMS/MIS-C are clinically significant indicators of disease severity that require vigilant monitoring and early immunomodulatory intervention. Continued multidisciplinary follow-up and prospective studies are essential to elucidate the long-term neurodevelopmental and psychiatric consequences and to optimize therapeutic strategies for these patients.

Open Access PDF

Concepts Keywords
encephalopathy
neuropsychiatric manifestations
pediatric neurology
PIMS/MIS-C * SARS-CoV-2
post-infectious complications
systemic hyperinflammation

Semantics

Type Source Name
disease MESH Pediatric Inflammatory Multisystem Syndrome
disease MESH severe acute respiratory syndrome
disease MESH infection
disease MESH included
disease MESH headache
disease MESH encephalopathy
disease MESH seizures
disease MESH acute disseminated encephalomyelitis
disease MESH syndrome
disease MESH cerebral edema
disease MESH hallucinations
disease MESH delirium
disease MESH anxiety
disease MESH sleep disorders
drug DRUGBANK Immune Globulin Human
disease MESH mul
disease MESH SARS CoV 2 infection
disease MESH ischemic stroke
disease MESH fever
disease MESH inflammation
disease MESH Kawasaki disease
disease MESH death
drug DRUGBANK Coenzyme M
disease MESH neuroinflammatory disorders
disease MESH neurological manifestations
disease MESH viral CNS infections
disease MESH toxic shock
disease MESH stroke

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *